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Introduction: The use of mitral balloon valvuloplasty as a percutaneous intervention for mitral stenosis has been
shown to be efficacious. Cardiac tamponade is a rare but serious complication of this procedure. Despite the low incidence
of this event, cardiac tamponade is well-reported in the literature. The management strategy of this complication involves
pericardial drainage and correction of coagulopathy, followed by surgical exploration if these interventions fail. With this
case report, we demonstrate the successful application of activated factor VII in the management of bleeding after
balloon valvuloplasty that persisted despite the standard treatments described above.
Case presentation: Our patient was a 31-year-old Yemenite man with no significant past medical history, who
presented with progressively worsening dyspnea on exertion and limited functional capacity over the last few years. A
transesophageal echocardiogram revealed severe mitral stenosis, which was treated with a mitral valve valvuloplasty.
The procedure was complicated by significant mediastinal bleeding that did not respond to routine maneuvers, which
included pericardiocentesis and correction of coagulopathy. Our patient was evaluated for surgical intervention but
responded to treatment with activated factor VII.
Conclusion: Factor VII may be used in the treatment of refractory mediastinal bleeding secondary to mitral
valvuloplasty prior to attempting surgical repair, and therefore may spare the patient the morbidity associated with
surgery.
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Cardiac perforation during cardiac catheterization pro-
cedures is very rare and only about one third result in
some degree of cardiac tamponade [1-10]. The proce-
dures responsible for the highest incidence of cardiac
tamponade include percutaneous mitral valvuloplasty
[11]. The incidence of cardiac tamponade during mitral
balloon valvuloplasty (MBV) is reported to be between
1% and 9% [1-7]. The presence of cardiac tamponade is
an absolute indication for emergent pericardial drainage
and can be performed by either pericardiocentesis or sur-
gical pericardiotomy [11,12]. Additional interventions that
should be considered include correction of coagulopathy* Correspondence: iog9001@nyp.org
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reproduction in any medium, provided the orwith protamine, fresh frozen plasma, cryoprecipitate and
platelets, and resuscitation with blood transfusions and
intravenous fluids [1,8,11,13,14]. These interventions are
often successful in controlling bleeding within several
hours [8]. Intractable bleeding requires a sternotomy. In
this report, we describe the successful application of acti-
vated factor VII (aFVII) in the management of persistent
bleeding during MBV, thereby avoiding a sternotomy and
the associated morbidity of this approach.
Case presentation
Our patient was a 31-year-old Yemenite man, with no sig-
nificant past medical or surgical history, who was not on
anticoagulants. He presented with progressively worsening
dyspnea on exertion and limited functional capacity over
the last few years. His physical examination was significant
for an opening snap, a grade 2-3/6 diastolic murmur andtd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
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significant for a normal coagulation profile. Our patient’s
electrocardiogram showed left atrial enlargement and no
evidence of ventricular hypertrophy. A transesophageal
echocardiogram revealed normal left ventricular systolic
function with an ejection fraction of 60% and left atrial dila-
tion. The mitral valve was minimally calcified with mild
thickening limited to the leaflet margin without chordal in-
volvement. Characteristic echocardiographic features of
rheumatic mitral stenosis were present with a Wilkins score
of three [15]. The mean mitral gradient was 11mmHg and
the valve area was 1.1cm2. Given our patient’s age, New
York Heart Association Class III symptoms and mitral
valve morphology, he was deemed to be a good candidate
for MBV. Heparin was administered with an activated clot-
ting time measured as 272 seconds. Valvuloplasty was per-
formed utilizing a transeptal approach with a 26mm Inoue-
balloon catheter.
At the end of the procedure, our patient was noted to
have an effusion on the echocardiogram, with features of
cardiac tamponade. He was otherwise hemodynamically
stable. The effusion was treated with emergent pericardio-
centesis and a pericardial catheter was left for continuous
drainage. Pericardial catheter output ceased after the drain-
age of approximately one liter of blood. An hour after ar-
rival to the intensive care unit, a pericardial effusion was
noted again on surveillance transthoracic echocardiog-
raphy. Our patient drained 350ml/h of bright red blood
for the next three hours despite a normal coagulation
profile. During this time, his presumed coagulopathy was
corrected with protamine (25mg intravenously), two units
of fresh frozen plasma, two single donor platelets and six
units of cryoprecipitate, and his coagulation profile then
rechecked. Complete evacuation of his pericardial sac
was verified hourly with surveillance transthoracic echo-
cardiography. Despite a normal coagulation profile the
bleeding persisted, with its exact site of origin unknown.
Our patient was warm, had normal acid-base status, and
remained hemodynamically stable throughout, yet an add-
itional 350cc of blood was drained within the next hour.
At that time, the decision was made to administer 4.8mg
(70μg/kg) of aFVII intravenously over two minutes. Drain-
age from the pericardial tube almost immediately ceased.
Transesophageal echocardiography revealed resolution of
the hemopericardium.
Our patient is doing well two years after the MBV. He
has a mitral valve gradient of 4mmHg and he has func-
tionally improved to New York Heart Association Class
I. His coagulopathy work-up was negative.
Discussion
To the best of our knowledge, this is the first report of
successful use of aFVII in the management of intractable
bleeding after MBV despite maximum medical therapy.An algorithm for management of postprocedural medi-
astinal bleeding usually involves placement of medias-
tinal drainage catheter and correction of coagulopathy.
If bleeding is refractory and/or the patient becomes
hemodynamically unstable, surgical intervention should be
considered. In our case, our patient was hemodynamically
stable yet had persistent bleeding that did not respond to
the correction of coagulopathy and mediastinal drainage.
Given our growing experience with use of aFVII in cardiac
surgery and the relative stability of our patient, we decided
to administer aFVII, with plans for transport to the operat-
ing room if bleeding did not subside. Drainage from the
mediastinal tube almost immediately ceased after aFVII
was administered.
Current indications for the use of aFVII are congenital
factor VII deficiency, hemophilia and Glanzmann throm-
basthenia. Despite its high cost (US$1 per microgram),
there has recently been an influx of research citing in-
creased off-label use of aFVII in the management of in-
tractable bleeding, in not only cardiac surgery [16] but
also intracranial hemorrhage, trauma, liver transplant-
ation and prostatectomy [17]. Factor VII plays a very im-
portant role in the initiation of coagulation by combining
with tissue factor (TF). Factor VII is constantly circulating
in the bloodstream and is not exposed to TF until there is
an injury to a blood vessel [16]. The activity of both factor
VII and TF are required to initiate coagulation and this is
accomplished when the TF/factor VIIa complex works in
conjunction with the factor VIII/IX complex to activate
factor X, which in turn is required for thrombin gener-
ation [16]. It has been shown that at certain dosing levels
aFVII can bypass the requirement of factors VIII and
IX and independently activate factor X. Additionally,
it has been shown to normalize prothrombin times in
patients with thrombocytopenia by improving platelet
function [16]. The end effect is a thrombin burst and
platelet activation that leads to a more effective platelet
plug formation.
Conclusion
aFVII may be considered prior to surgical intervention in
hemodynamically stable patients in the context of medias-
tinal bleeding refractory to medical therapy after MBV.
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